From genomics to drug targets

Journal of Psychopharmacology

Volumn 20, Issue 4 SUPPL., 2006, Pages 95-99

  Dahl, Svein G ^a   Sylte, Ingebrigt ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Molecular dynamics; Molecular mechanisms; Molecular structure; Receptors; Transporters

Indexed keywords

CARRIER PROTEIN; COTRANSPORTER; DNA; ENZYME; ION CHANNEL; LACTOSE PERMEASE; MEMBRANE PHOSPHOLIPID; MEMBRANE PROTEIN; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; PSYCHOTROPIC AGENT;

AQUEOUS SOLUTION; ARTICLE; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; CRYSTALLIZATION; DNA SEQUENCE; ELECTRON MICROSCOPY; HUMAN; HYDROPHOBICITY; MOLECULAR BIOLOGY; MOLECULAR CLONING; MOLECULAR DYNAMICS; MOLECULAR MODEL; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PURIFICATION; SEQUENCE ANALYSIS; STRUCTURAL BIOINFORMATICS; STRUCTURE ANALYSIS;

ANIMALS; BINDING SITES; GENOMICS; HUMANS; MEMBRANE PROTEINS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; PSYCHOTROPIC DRUGS; RECEPTORS, DRUG;

EID: 33750039998     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/1359786806066088     Document Type: Article

References (40)

1. Abbott A (2005) Protein structures hint at the shape of things to come. Nature 435: 547
2. Altshuler D, Brooks L D, Chakravarti A, Collins F S, Daly M J, Donnelly P (2005) A haplotype map of the human genome. Nature 437: 1299-1320
3. Blakely R D, Berson H E, Fremeau R T, Jr., Caron M G, Peek M M, Prince H K, Bradley C C (1991) Cloning and expression of a functional serotonin transporter from rat brain. Nature 354: 66-70
4. Breckenridge A, Lindpaintner K, Lipton P, McLeod H, Rothstein M, Wallace H (2004) Pharmacogenetics: ethical problems and solutions. Nat Rev Genet 5: 676-680
5. CIOMS (2005) Pharmacogenetics. Towards Improving Treatment with Medicines. Working Group, Council for International Organisations of Medical Sciences (CIOMS), Geneva
6. Dahl S G, Sylte I (2005) Molecular modelling of drug targets: the past, the present and the future. Basic Clin Pharmacol Toxicol 96: 151-155
7. Dahl S G, Edvardsen O, Sylte I (1991) Molecular dynamics of dopamine at the D2 receptor. Proc Natl Acad Sci U S A 88: 8111-8115
8. Dahl S G, Ravna A W, Sylte I (2004) Structures and models of transporter proteins. J Pharmacol Exp Ther 309: 853-860
9. Dahl S G, Edvardsen Ø, Heimstad E, Sylte I (1989) Three dimensional structure of the dopamine D2 receptor. In Stefanis C N, Soldatos C R, Rabavilas A D (eds), VIII World Congress of Psychiatry. Excerpta Medica, Athens, Greece: 489
10. Drews J (2000) Drug discovery: a historical perspective. Science 257: 1960-1964
11. Edvardsen O, Dahl S G (1994) A putative model of the dopamine transporter. Brain Res Mol Brain Res 27: 265-274
12. Edvardsen O, Sylte I, Dahl S G (1992) Molecular dynamics of serotonin and ritanserin interacting with the 5-HT2 receptor. Brain Res Mol Brain Res 14: 166-178
13. EMEA (2002) Position paper on terminology in pharmacogenetics. The European Agency for the Evaluation of Medicinal Products (EMEA), Committee for proprietary medicinal products, London, EMEA/CPMP/3070/01, pp. 1-6
14. Giros B, el Mestikawy S, Bertrand L, Caron M G (1991) Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295: 149-154
15. Goodman L S, Limbird L E, Milinoff P B, Ruddon R W, Gilman A G, Hardman J G (eds) (1996) Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill, New York.
16. Guastella J, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel M C, Davidson N, Lester H A, Kanner B I (1990) Cloning and expression of a rat brain GABA transporter. Science 249: 1303-1306
17. Haga S B, Burke W (2004) Using pharmacogenetics to improve drug safety and efficacy. Jama 291: 2869-2871
18. Henderson R, Unwin P N (1975) Three-dimensional model of purple membrane obtained by electron microscopy. Nature 257: 28-32
19. Hjerde E, Dahl S G, Sylte I (2005) Atypical and typical antipsychotic drug interactions with the dopamine D2 receptor. Eur J Med Chem 40: 185-194
20. Hopkins A L, Groom C R (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730
21. Huang Y J, Montelione G T (2005) Proteins flex to function. Nature 438: 36-37
22. Kristiansen K (2004) Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. Pharmacol Ther 103: 21-80
23. Langley J N (1878) On the physiology of salivary secretion. Part II. On the mutual antagonism of atropin and pilocarpin, having especial reference to their relations in the sub-maxillary gland of the cat. J Physiol 1: 339-369
24. Langley J N (1905) On the reaction of cells and of nerve endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol 33: 374-413
25. Lesko L J, Woodcock J (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 3: 763-769
26. Lindorff-Larsen K, Best R B, Depristo M A, Dobson C M, Vendruscolo M (2005) Simultaneous determination of protein structure and dynamics. Nature 433: 128-132
27. Meyer U A (2004) Pharmacogenetics - five decades of therapeutic lessons from genetic diversity. Nature Reviews Genetics 5: 669-676
28. Pacholczyk T, Blakely R D, Amara S G (1991) Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350-354
29. Palczewski K, Kumasaka T, Hori T, Behnke C A, Motoshima H, Fox B A, Le Trong I, Teller D C, Okada T, Stenkamp R E, Yamamoto M, Miyano M (2000) Crystal structure of rhodopsin: a G protein-coupled receptor. Science 289: 739-745
30. + antiporter NhaA. Receptors Channels 7: 319-328
31. Ravna A W, Sylte I, Dahl S G (2003a) Molecular mechanism of citalopram and cocaine interactions with neurotransmitter transporters. J Pharmacol Exp Ther 307: 34-41
32. Ravna A W, Sylte I, Dahl S G (2003b) Molecular model of the neural dopamine transporter. J Comput Aided Mol Des 17: 367-382
33. Ravna A W, Sylte I, Kristiansen K, Dahl S G (2006) Putative drug binding conformations of monoamine transporters. Bioorg Med Chem 14: 666-675
34. Roses A D (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5: 645-656
35. Schertler G F, Villa C, Henderson R (1993) Projection structure of rhodopsin. Nature 362: 770-772
36. Sylte I, Bronowska A, Dahl S G (2001) Ligand induced conformational states of the 5-HT(1A) receptor. Eur J Pharmacol 416: 33-41
37. Vogel F (1959) Moderne Probleme der Humangenetik. Ergebn Inn Med Kinderheilkd 12: 52-125
38. Weinshilboum R, Wang L (2004) Pharmacogenomics: bench to bedside. Nat Rev Drug Discov 3: 739-748
39. Williams K A (2000) Three-dimensional structure of the ion-coupled transport protein NhaA. Nature 403: 112-115
40. Yamashita A, Singh S K, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437: 215-223